GLOBUS MEDICAL INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $GMED in the last 7 days.
No SEC Form 4 filings for $GMED in the last 30 days.
See all $GMED insider activity →Globus Medical (NYSE:GMED) will release Q3 2026 earnings after market close on Nov. 5, 2026, followed by a conference call at 4:30 p.m. ET. The company, a musculoskeletal technology firm, will discuss performance with investors. Details and access to the call are available on their investor relations website.
TOBIN JAMES R sold 30,000 shares of GLOBUS MEDICAL INC (GMED) at $74.58 ($2.24M total) on 2026-09-15.
Zacks upgraded five stocks to Strong Buy: RCM Technologies (RCMT), Healthcare Services Group (HCSG), Bloomin' Brands (BLMN), Argan (AGX), and Globus Medical (GMED). Their earnings estimates rose 13.3%, 12.9%, 10.1%, 6.7%, and 5.3% respectively in 60 days.
Recent GMED coverage spans regulation, mergers & acquisitions and earnings.
The upcoming earnings announcement may drive short-term volatility and trading interest around the release.
Significant insider sell by a director may signal lack of confidence, potentially pressuring the stock.
Potential short‑term buying from rank‑followers.
Regulatory clearance expands market addressable size and could boost revenue growth.
The CE mark enables market entry in Europe, potentially expanding revenue and market share for Globus Medical.
AlphAI scores every news story that mentions GMED with an AI model for sentiment and relevance, and aggregates insider trades from GLOBUS MEDICAL INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Globus Medical (NYSE:GMED) will release Q3 2026 earnings after market close on Nov. 5, 2026, followed by a conference call at 4:30 p.m. ET. The company, a musculoskeletal technology firm, will discuss performance with investors. Details and access to the call are available on their investor relations website.
1 min readTOBIN JAMES R sold 30,000 shares of GLOBUS MEDICAL INC (GMED) at $74.58 ($2.24M total) on 2026-09-15.
1 min readZacks upgraded five stocks to Strong Buy: RCM Technologies (RCMT), Healthcare Services Group (HCSG), Bloomin' Brands (BLMN), Argan (AGX), and Globus Medical (GMED). Their earnings estimates rose 13.3%, 12.9%, 10.1%, 6.7%, and 5.3% respectively in 60 days.
1 min readGlobus Medical (GMED) announced its Excelsius3D imaging system received CE marking, allowing sales in the EU and UK. The system combines 3D cone-beam CT, 2D fluoroscopy, and digital radiography for surgical use. CEO Keith Pfeil highlighted the milestone's importance for the Excelsius Ecosystem. The company has been active in M&A and product development, including acquiring Higgs Boson Health and Nevro.
2 min readGlobus Medical (GMED) received CE mark approval for its Excelsius3D imaging system, allowing commercial sales in the EU and UK. The system integrates 3D CT, 2D fluoroscopy, and digital radiography, enhancing the ExcelsiusGPS robotic navigation system. The company plans to begin commercialization in these markets, following FDA clearance in the US in 2021.
2 min readGlobus Medical (GMED) shares rose 1% after-hours after receiving CE mark approval for its Excelsius3D imaging system in the EU and UK. The system integrates with the company's ExcelsiusGPS robotic navigation system and was previously cleared by the FDA in 2021. The company plans to commercialize the product in these markets.
2 min readGlobus Medical (GMED) shares fell 3.1% despite a new product milestone in Europe. Investors focused on growth concerns from August's earnings, which showed 5.9% revenue growth. Analysts noted mixed sentiment on growth pace and integration of acquired businesses.
2 min readGlobus Medical has received approval from the EU and UK to market its Excelsius3D imaging platform. The company's stock is currently trading at 78.12 USD, with a 5-day change of -3.15% and a year-to-date change of -10.53%.
1 min readGlobus Medical, Inc. has acquired Higgs Boson Health, a digital healthcare company from Duke University. The deal integrates Higgs Boson's AI and software teams into Globus to create a connected digital care platform for musculoskeletal patients. Financial details were not disclosed.
2 min readGlobus Medical Inc (GMED) acquired Higgs Boson Health to enhance its digital capabilities with AI-driven analytics. GMED's stock is 14.2% undervalued at $83.10 vs. GF Value™ of $96.83, with a GF Score™ of 94. Insider selling totals $15.9M, while 8 gurus hold the stock. GMED's P/E ratio is 21.25x, below its 5-year median of 40.78x.
2 min read
